Phaseline

Targets › PTPN11

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Positively regulates MAPK signal transduction pathway. (UniProt, Q06124)

Open in Phaseline: the race on PTPN11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Allist PharmaceuticalsJAB-3312
SHP2 inhibitor
PTPN11Phase 3Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12CMar 2027
HUYABIO InternationalHBI-2376
SHP2 inhibitor
PTPN11Phase 1Non Small Cell Lung CancerDec 2026
NovartisBatoprotafib (TNO155)
Protein-tyrosine phosphatase 2C inhibitor
PTPN11Phase 1KRAS G12C Mutant Solid TumorsJan 2027

Conditions

Non Small Cell Lung Cancer (1) KRAS G12C Mutant Solid Tumors (1) Advanced Non-squamous Non-small-cell Lung Cancer (1) KRAS P.G12C (1)

Modalities

small molecule (2), mixed (1)

Companies

HUYABIO International (1) Novartis (1) Allist Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.